Vicore Pharma Holding AB

The current price of VCRE is $9.44 — it has increased by 1.18% since the previous close. Data as of Nov 4, 2026.

VCRE is down 5.88% over the past week, up 1.18% over the past month and down 41.91% over the past year. The price is below its 200-day moving average of $10.97.

Analysts' average 12-month price target for VCRE is $25.00, which implies 164.83% upside from the current price. Individual estimates range from $25.00 to $25.00.

Of the 2 analysts covering Vicore Pharma Holding AB, 2 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Vicore Pharma Holding AB has a market capitalization of $266.66M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Vicore Pharma Holding AB posted a loss of $0.5146 per share against an estimate of -$0.4216, missing expectations by 22.07%. Upcoming reports are listed in the earnings calendar.

Vicore Pharma Holding AB reported revenue of $222K in its most recent quarter. Analysts had expected $477K.

Companies most comparable to Vicore Pharma Holding AB include Liquidia Corporation and Avalyn Pharma Inc. Common Stock.

In the latest trading session VCRE moved between $9.34 and $9.74, a range of 4.24% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Vicore Pharma Holding AB shows a sell rating today. Technical ratings are indicators, not investment advice.

Over the past 52 weeks VCRE has traded between $7.88 and $17.80. The current price is 46.97% below its 52-week high.